Cross‐sectional and Mendelian randomization study of fibroblast growth factor 19 reveals causal associations with metabolic diseases

Fibroblast growth factor 19 (FGF19) is an intestinal-derived factor that plays a role in metabolic diseases. We performed a differential study of circulating FGF19 levels and investigated the causal effects of FGF19 on metabolic diseases using Mendelian randomization (MR).